Pharmaceutical Executive Daily: FDA Requires Safety Label Update on GLP-1 Receptor Agonist

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, the FDA approves Bayer’s asundexian as the first Factor XIa inhibitor worldwide for secondary stroke prevention, the FDA requires manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION, and AstraZeneca acquires Omniose to add a bioconjugation platform to its preclinical vaccine programs.

FDA approved Bayer’s asundexian, to be sold as Sunharbo, making it the first approved Factor XIa inhibitor worldwide for secondary stroke prevention in adults with a recent non-cardioembolic ischemic stroke or high-risk TIA. In the Phase III Oceanic-stroke trial, asundexian combined with antiplatelet therapy reduced ischemic stroke by 26% compared to antiplatelet therapy alone, with a similar rate of major bleeding to placebo.

In other regulatory news, FDA is requiring manufacturers of all GLP-1 receptor agonists, including semaglutide, tirzepatide, and orforglipron, to update labeling with a warning for a potential increased risk of non-arteritic anterior ischemic optic neuropathy. A meta-analysis of 126 clinical trials covering more than 134,000 patients found an incidence rate of 6.4 NAION cases per 100,000 person-years among GLP-1 users, compared with 3.8 among comparator-treated patients.

Finally, AstraZeneca acquired Omniose, following a three-year exclusive research collaboration between the two companies, bringing Omniose’s proprietary bioconjugation platform into AstraZeneca’s Infectious Disease Unit. The technology offers an alternative to chemical cross-linking in conjugate vaccine manufacturing, and will support AstraZeneca’s existing preclinical programs targeting serious bacterial infections; financial terms were not disclosed.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.